Agenda for SPL Generic Sub Team Meeting
January 13, 2009






  1. Meeting minutes from 12/15/08 – are posted on the Wiki site – any questions, additions, etc?
Meeting minutes were accepted and there were no questions.

  1. Reminder - beginning in January we will meet every 4th Tuesday.
Nothing to add

  1. Tom Marsden, Ryan Paul & Julie Newman/D&B presentation & Q&A session.
If you are not an existing D&B customer you can contact Julie Newman to set up an account for SPL DUNS#s only.
Julie Newman
�1637�703.807.5091
Tom Marsden, Julie Newman, and Ryan Paul were on the teleconference. Dun And Bradstreet is still working on a solution to get the D-U-N-S numbers out. D&B is working with vendors as well as up-staffing for this.

When we contact D&B, they would like to update their information about the company that is contacting them. This will help keep the information current.

Remember the D-U-N-S numbers is being used as part of the information to validate the SPL submission.


Ryan Paul PaulR@DNB.com
Julie Newman NewmanJu@DNB.com

Tom Marsden MarsdenT@DNB.com

Regarding costs – these are still not determined. For D-U-N-S numbers inside the corporate family tree, these numbers are not charged for. External one are charged for but the price points are not fully determined.

Again, there are three methods of getting trading partner information:
1) However it has been done in the past
2) Contact the above 3 at D&B
3) Go to the vendors who are supplying this information

D&B will be at the Face-to-Face meeting in May.


The SPL group still needs

  • the cost structure
  • a definition of corporate family tree
  • speed of response and turn-around of request
    • for trading partner information that exists
    • for trading partner information that has to be generated
  • a quick way to find who in the sponsor company is responsible for the D-U-N-S numbers; whether it is a purchasing, legal or other department

Many other questions were asked. Most of these should be in the FAQ. See:
http://spl-work-group.wikispaces.com/DUNS+Number+FAQ

4. Please note: One item from the Leadership team meeting is that the FDA is recommending that each company which does not have a gateway account already should obtain one ASAP.
Link here: http://spl-work-group.wikispaces.com/Electronic+Submission+Gateway+%28ESG%29
Do it!!!

  1. FDA Training webinars and F2F meeting May 21, 2009. SPL Vendor training webinar 02/04/09.

  1. Prototype stylesheets from SPL R3 & R4.

  1. OTC vendor webinars – we will keep you informed.
Please see the Wiki for presenters, dates and times. Also there are copies of the presentations on the Wiki at:
http://spl-work-group.wikispaces.com/OTC
at the Vendor Presentations sub-head.


  1. Companies registered electronically will now have their DUNS numbers on the site.

  1. Questionnaire on Wiki site – Jeffery Karp. (PDF of Survey attached.)
The PDF of the survey is on the Wiki on the Generics page. Jeffery Karp described the survey and how to use it.
Note: Post the meeting, a note was sent out inviting you to take the survey. Please do this and let us know your information and any comments you have on the survey.


  1. Any other business.

Generic Sub Team Attendees
For meeting 1/13/09



Name
Company
E-mail
Blik, Cheryl
Teva Pharmaceuticals
Cheryl.Blik@tevausa.com
Brandt, Richard
InVision Research
RBrandt@invisionresearch.com
Brunone, Theresa
Glaxo Smith Kline
Theresa.Brunone@gsk.com
Cekic, Fatima
Caraco Pharm Labs, Ltd
�1700��1335��1336��1337��1338�Cobham, Michele
Par Pharmaceutical
Michele.Cobham@parpharm.com
Desai, Mona
Interchem
�1706��1351��1352��1353��1354�Fariman, Denise
Lannett Company, Inc.
DFairman@lannett.com
Frahn, Jane + 1 team member
Teva Pharmaceuticals
Jane.Frahn@tevausa.com
Harvey, Mary
Qualitest Pharmaceuticals
MHarvey@qualitestrx.com
Hewitt, Michele
Sandoz
�1718��1383��1384��1385��1386�Hogan, Virginia
Generic Sub Team Leader
Teva Pharmaceuticals
Virginia.Hogan@tevausa.com
Karp, Jeffery
Generics Sub Team Co Leader
RA/IT Associates
JMKarp01@comcast.net
Keller, Jamie
Glenmark Generics, Inc
JamieK@glenmark-generics.com
Kirkeleit-Davis, Jean
Hospira

Kirkner, Ruth
Teva Pharmaceuticals
Ruth.Kirkner@tevausa.com
Lee, Koung
FDA, Office of Generic Drugs
Koung.Lee@fda.hhs.gov
Lempka, Gayle
Watson
Gayle.Lempka@watson.com
Mohammed, Suraya
GPhA
�1744��1447��1448��1449��1450�Nestoros, Susan
Barr Laboratories, Inc
�1747��1455��1456��1457��1458�Nguyen, Wafa
Qualitest Pharmaceuticals
WNguyen@qualitestrx.com
O’Sullivan, Kathleen
Barr Laboratories, Inc.
�1753��1471��1472��1473��1474�Patel, Shilpa
Caraco Pharmaceutical Labs, Ltd.
Shilpa.Patel@caraco.com

Peritore, Sal
Barr Laboratories, Inc
�1760��1487��1488��1489��1490�Pomraning, Jennifer
Mylan Labs
Jennifer.Pomraning@mylan.com
Roy, Milon
Unichem
�1766��1503��1504��1505��1506�Saner, Gary
Reed Technology
GSaner@reedtech.com
Santoro, Amanda
Hospira
Amanda.Santoro@hospira.com
Shieh, Betty
Teva Pharmaceuticals
Betty.Shieh@tevausa.com

Tenaglia, Paul
Apotex, Inc.
PTenaglia@apotex.com

Troutman, Craig
Intagras
CTrautman@intagras.com
Vasquez, Karen
Roxane Laboratories, Inc
�1786��1551��1552��1553��1554�Vu, Ann
FDA, Office of Generics Drugs
Thuyanh.Vu@fda.hhs.gov

Wells, Hollie
Sandoz
Hollie.Wells@sandoz.com




Additions to the meeting:
Jeff Poisson – jpoisson@i4i.com
Marueen Kapustnski – maureen.kapustnski@cs-americas.com
Juris Lazdinis – juris.lazdins@novartis.com
Howard Shatz – hshatz@dclab.com
Theresa Gerardi – theresa.gerardi@barrlabs.com
Nicholas Romano – Nicholas.romano@novartis.com

3 from D& B:
Ryan Paul PaulR@DNB.com
Julie Newman NewmanJu@DNB.com

Tom Marsden MarsdenT@DNB.com